FIGURE 5.
Kaplan–Meier survival curve for drug persistence after the switch from IV to SC vedolizumab treatment. Events refer to treatment discontinuation. Censored points refer to patients that have not yet completed 12 months of follow‐up
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.